Enhancing Bone Regeneration and Osseointegration using rhPTH(1-34) and DimericR25CPTH(1-34) in an Osteoporotic Beagle Model

Abstract

AbstractIntroductionDespite continuous parathyroid hormone (PTH) exposure potentially accelerating bone resorption, intermittent PTH administration has shown anabolic effects on bone microarchitecture. This study investigates the therapeutic impacts of two PTH analogs, rhPTH(1-34) and dimericR25CPTH(1-34) on bone regeneration and osseointegration in a postmenopausal osteoporosis animal model.MethodsTwelve female beagles, osteoporotic post-ovariectomy, underwent implant surgeries. Animals were divided into three groups: control, daily rhPTH(1-34) injection, and daily dimericR25CPTH(1-34) injection. After 10 weeks, bone regeneration and implant osseointegration were evaluated using micro-CT, histological/histomorphometric analyses, and serum biochemical analysis.ResultsWhile the rhPTH(1-34) group demonstrated improved microarchitectural characteristics, such as BMD, BV, trabecular metrics, and osseointegration degree, the dimericR25CPTH(1-34) group showed similarly enhanced anabolic effects around the titanium implants, albeit these were less pronounced than the rhPTH(1-34), yet significantly better than the control group. Histologic and TRAP assays revealed that both PTH analogs significantly promoted bone regeneration and remodeling, especially in artificially created bone defects.ConclusionThis study demonstrated the therapeutic effects of rhPTH(1-34) and dimericR25CPTH(1-34) on bone regeneration and titanium osseointegration in a beagle model with osteoporosis.